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Purpose: To investigate the association between Apolipoprotein E (APOE), tumor suppressor protein p53 (p53), and
cyclin-dependent kinase inhibitor 1A (p21) genes and primary open-angle glaucoma (POAG) in a cohort of Turkish
subjects.
Methods: Seventy-five POAG patients (49 women, 26 men) and 119 healthy subjects (67 women, 52 men) were genotyped
with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Allele and genotype frequencies
between healthy subjects and glaucoma patients were compared by the χ2 test, and intraocular pressure (IOP), cup/disc
ratio (C/D) and visual field indices (MD and PSD) were compared among different APOE, p53, and p21 genotypes in
POAG group. A p value <0.05 was considered as statistically significant.
Results: The mean ages were 63.8±9.5 and 61.8±10.2 years in POAG and control groups, respectively (p=0.18). There
were no significant differences in the distribution of APOE, p53, and p21 genotypes between the healthy subjects and
POAG patients (p=0.38, p=0.12, and p=0.2, respectively). There were no significant differences in maximum IOP, MD,
and PSD values among different groups of p53 and p21 genotypes (p>0.05). POAG subjects with the ε2ε3 genotype had
a worse PSD value (median=2.2) than those with the ε3ε4 genotype (median=1.77; p=0.01) and POAG subjects with the
ε3ε3 genotype had worse MD and PSD values (median= -7.4 and 3.4, respectively) than those with the ε3ε4 genotype
(median= -4.1 and 1.77, respectively; p=0.034 and 0.028, respectively).
Conclusions: Our study found no link between polymorphisms in APOE, p53, and p21 genes and POAG in Turkish
patients, although a larger sample is required to elucidate the role of these polymorphisms in the pathogenesis and course
of glaucoma.
Glaucoma  is  a  degenerative  optic  neuropathy,
characterized by optic nerve head (ONH) changes and visual
field loss. Elevated intraocular pressure (IOP) is generally
accepted as the major modifiable risk factor for glaucoma,
however,  factors  other  than  IOP  also  play  role  in  the
pathogenesis and progression of glaucoma, particularly in
subjects with normal tension glaucoma (NTG). It is the second
leading cause of blindness worldwide, estimated to affect
about  70  million  people,  with  6.7  million  of  these  being
bilaterally blind [1]. Primary open-angle glaucoma (POAG,
OMIM 137760) is the major type of primary glaucoma in most
populations. POAG is a genetically heterogeneous disorder
and at least 22 genetic loci have been mapped for POAG of
which only GLC1A (myocilin, MYOC), GLC1E (optineurin,
OPTN),  GLC1G  (WD  repeat  domain  36,  WDR36),  and
GLC3A  (cytochrome  P4501B1,  CYP1B1)  have  been
characterized  [2-7].  However,  mutations  in  these  genes
account for less than 10% of POAG cases. It appears that
POAG is a complex trait and multiple genes, each with allelic
variations,  and  environmental  factors  contribute  to  the
Correspondence to: Dr. Ay Ogus, Hacettepe University, Biology,
Beytepe,  Ankara,  06800,  Turkey;  Phone:  903122978020;  FAX:
903122992028; email: bioarzu@hacettepe.edu.tr
pathogenesis  and  phenotype  and  increase  individual’s
susceptibility  to  glaucomatous  optic  neuropathy,  with  no
particular gene having a single dominant effect.
Apolipoprotein  E  (APOE),  which  is  the  major
apolipoprotein  in  the  central  nervous  system,  plays  an
important role in neural function and repair after injury. APOE
is up-regulated in response to oxidative stress and is endowed
with antioxidant properties [8]. It exists as three common
isoforms E2, E3 and E4, encoded by different alleles (ε2, ε3,
and  ε4)  on  a  single  gene  on  chromosome  19  (OMIM
107741).  Possession  of  the  ε4  allele  was  shown  to  be
associated with a reduced outcome after traumatic head injury
[9,10]  and  increased  risk  of  earlier  development  of
Alzheimer’s disease [11,12]. In the rat eye, it has been shown
to be synthesized by Müller cells, secreted in the vitreous,
absorbed by the retinal ganglion cells (RGC), and transported
down  the  optic  nerve  [13].  Its  possible  role  in  RGC
metabolism, together with its documented effect on neuronal
survival following ischemic and traumatic insults, has led to
the hypothesis that particular APOE isoforms could be related
to neuronal damage in glaucoma patients [14]. Given the
potential similarities between the cellular events leading to
degeneration in both Alzheimer’s disease and glaucoma, the
higher incidence of glaucoma in Alzheimer’s disease [15,16]
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1270and APOE ε4 allele as a risk factor for Alzheimer’s disease,
APOE  seems  to  be  a  pliable  candidate  for  glaucoma
susceptibility. In the literature, some of the studies showed an
association  between  certain  types  of  APOE  alleles  and
glaucoma [14,17-21], whereas others found no association
[22-25].
Apoptosis  is  a  form  of  genetically  controlled,
programmed  cell  death  and  an  important  mechanism
responsible for RGC death in glaucoma [26,27]. One of the
primary regulatory steps of apoptosis is the activation of the
tumor suppressor protein, p53, which is encoded by the TP53
gene  (guardian  of  the  cell)  located  on  the  short  arm  of
chromosome 17 (17p13.1) in humans. p53 functions as a
transcription factor that can upregulate the expression of the
pro-apoptotic gene bax and downregulate the expression of
the antiapoptotic gene bcl-2. This protein has been described
as "the guardian of the genome," "the guardian angel gene,"
and the "master watchman," referring to its role in conserving
stability by preventing genome mutation [28]. Mutations of
p53  have  been  detected  in  almost  50%  of  human
malignancies, since the mutant or inactivated p53 protein fails
to initiate the apoptotic process and, consequently, genetically
damaged cells proliferate in an uncontrolled manner [29]. In
neurodegenerative processes and toxic neuronal injury, p53 is
upregulated, thereby promoting cell death through apoptosis
[30]. Genetic polymorphic variants of p53 were shown to be
associated with POAG [31,32].
Cyclin-dependent kinase (CdK) inhibitor 1A (p21, Cip1),
is a protein which in humans is encoded by the CDKN1A gene
located on chromosome 6. It is known to cause irreversible
G1 arrest in human fibroblasts by mediating the inhibition of
CdKs [33]. p21 is the major transcriptional target of p53;
despite this, loss-of-function mutations in p21 (unlike p53) do
not  predispose  to  cancer  incidence.  A  single  nucleotide
polymorphism  (SNP)  in  p21  which  consists  of  a  C  to  A
transverse change at the third base of codon 31, resulting in
the exchange of a Serine for an Arginine, has been reported
[34]. This codon 31 polymorphism is thought to encode a
DNA-binding zinc-finger domain [35]. A study on a Chinese
population showed an association between the Arg form of the
p21 codon 31 polymorphism and POAG, suggesting that this
allele may alter the state of apoptosis in glaucomatous optic
neuropathy, failing to protect the ganglion cells [36].
In the present study, we evaluated the genetic association
of APOE, p53, and p21 polymorphisms with POAG in a group
of  Turkish  subjects  and  investigated  their  possible
involvement with the disease phenotype and severity.
METHODS
The cases enrolled in this study were unrelated to each other
and were derived exclusively from the Turkish population. All
subjects have undergone systematic examination of optic disc,
visual field examination with automated static white on white
threshold  perimetry  using  the  30-2/24-2  program  of  the
Humphrey  Field  Analyzer  (Dublin,  CA),  and  IOP
measurement  with  Goldmann  applanation  tonometry.
Gonioscopy was utilized to confirm that all cases had open
angles. Patients were classified as having POAG based on
ONH  or  retinal  nerve  fiber  layer  (RNFL)  structural
abnormalities.  The  subjects  were  excluded  if  they  had
congenital glaucoma or secondary causes (such as pigment
dispersion,  pseudoexfoliation,  trauma,  uveitis,  or  steroid
induced glaucoma) for glaucoma. The control group consisted
of  patients  who  attended  the  ophthalmology  clinic  for
refractive errors, routine ophthalmic examination, or medical
staff with no ocular problems. They had no family history of
glaucoma and their IOP measurements were <21 mmHg on 2
different visits.
The study protocol was in adherence to the tenets of the
Declaration  of  Helsinki  and  approved  by  the  Ethics
Committee  of  Hacettepe  University  School  of  Medicine.
Informed consent was obtained from all study subjects after
explanation of the nature and possible consequences of the
study.
Genetic analysis: Venous blood was obtained from the
subjects and stored at -20 °C for less than three months before
DNA extraction. Genomic DNA was isolated from peripheral
blood using the phenol-chloroform extraction method. The
genotypes  of  APOE,  p53,  and  p21  polymorphisms  were
determined by the PCR-RFLP method.
APOE gene polymorphisms were investigated using the
primer  sequences  5’-GAA  CAA  CTG  ACC  CCG  GTG
GCG-3’ (forward) and 5’-GGA TGG CGC TGA GGC CGC
GCT-3’  (reverse).  PCR  products  were  checked  in  1.5%
agarose gel. For RFLP analysis, PCR product was digested
with HhaI at 37 °C overnight. Digested DNA fragments were
separated on 10% polyacrylamide gel electrophoresis and five
different APOE genotypes were observed (ε3/ε3, ε2/ε3, ε3/
ε4, ε2/ε4, and ε4/ε4).
For p53 gene polymorphisms, PCR was performed using
the primer sequences 5’-CCT GAA AAC AAC GTT CTG
GTA A-3’ (forward) and 5’-GCA TTG AAG TCT CAT GGA
AG-3’ (reverse) [32]. For RFLP analysis, PCR product was
digested  with  BstUI  at  37  °C  overnight.  Digested  DNA
fragments  were  separated  on  1.5%  agarose  gel
electrophoresis. Amplified PCR products for p53 with a C
nucleotide at codon 72 (Pro residue) remained undigested and
were 448 bp or 432 bp in length depending on whether the 16
bp insertion was present or not. Products with a G nucleotide
at  codon  72  (Arg  residue)  were  248  or  232  bp  in  length
depending whether the 16 bp insertion was present or not.
For p21 gene polymorphisms, PCR was performed using
the primer sequences 5’-GTC AGA ACC GGC TGG GGA
TG-3’ (forward) and 5’-CTC CTC CCA ACT CAT CCC
GG-3’ (reverse) [37]. For RFLP analysis, PCR product was
digested  with  BlpI  at  37  °C  overnight.  Digested  DNA
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The Ser allele has a single BlpI restriction site (GCTNAGC),
resulting in two fragments of 89 bp and 183 bp and the Arg
allele remains undigested, producing a single band of 272 bp.
Statistical  analysis:  Genotypic  distributions  were
examined for significant deviation from the Hardy-Weinberg
equilibrium by a goodness of fit χ2 test. The frequencies of
genotypes and alleles were compared among glaucoma and
healthy  subjects  using  χ2  test,  whereas  non-parametric
Kruskal-Wallis  and  Mann-Whitney  U  tests  were  used  to
evaluate the differences in maximum IOP, cup/disc ratio (C/
D),  MD  and  PSD  values  among  APOE,  p53,  and  p21
genotypes in POAG group and p<0.05 was considered as
statistically significant.
RESULTS
Seventy-five POAG patients (49 women, 26 men) and 119
healthy subjects (67 women, 52 men) were included in the
study. The mean ages were 63.8±9.5 and 61.8±10.2 years in
POAG and control groups, respectively (p=0.18). In POAG
group, the mean±standard deviations (SD) of the IOP, C/D,
MD and PSD were 26.8±3.5 mmHg, 0.6±0.2, 9.7±7.7 dB, and
5.2±4 dB, respectively. The distribution of genotypes was
given in detail in Table 1. The observed genotypes did not
show  deviation  from  the  Hardy-Weinberg  equilibrium  in
either  the  cases  or  the  controls  (p>0.05).  There  were  no
significant differences in the distribution of APOE, p53, and
p21  genotypes  between  the  healthy  subjects  and  POAG
patients (p=0.39, p=0.12, and p=0.28 respectively). For the
exon 4 polymorphism, five genotypes including ε3/ε3, ε2/ε3,
ε3/ε4, ε2/ε4, and ε4/ε4 were observed in our study subjects.
APOE ε3/ε3 was the most common genotype observed both
in the glaucoma and the control groups, whereas genotype ε2/
ε2 was not detected in both groups. The genotypes ε2/ε4 and
ε4/ε4 were rare both in POAG and control groups. APOE
allele frequencies also did not differ among POAG and control
groups (p=0.14; Table 1).
There were no significant differences in maximum IOP,
MD, and PSD values among different groups of p53 and p21
genotypes  (Table  2).  For  APOE  polymorphisms,  these
parameters were similar in ε2ε3 and ε3ε3, with no statistically
significant differences, whereas POAG subjects with the ε2ε3
genotype had worse visual field defects (median PSD=2.2)
than  those  with  the  ε3ε4  genotype  (median  PSD=1.77;
p=0.01) and POAG subjects with the ε3ε3 genotype had worse
MD and PSD values (median= -7.4 and 3.4, respectively) than
those  with  the  ε3ε4  genotype  (median=  -4.1  and  1.77,
respectively;  p=0.034  and  0.028,  respectively).  Only  one
subject had the ε2ε4 genotype and he had very advanced
glaucoma and one subject with early stage glaucoma had the
ε4ε4 genotype.
DISCUSSION
Glaucoma is a neurodegenerative disease with multiple genes
contributing  to  the  pathogenesis,  clinical  features  and
response to treatment. Genetic association studies defining
susceptibility to POAG may provide important insights into
the pathogenesis, but should be treated with caution until the
findings are independently replicated.
In this study, we could not show an association between
APOE  genotypes/alleles  and  POAG.  The  most  common
genotype was ε3/3 observed in 70.7% of our patients with
POAG and 73.9% of the control subjects and the ε3 allele was
observed in 84% of patients with POAG and 85.7% of control
subjects, which were not statistically different. The frequency
of the APOE ε4 allele in our control and POAG groups were
10.1% and 7.3%, respectively. POAG subjects with ε2ε3 and
TABLE 1. APOE, P53, AND P21 GENOTYPE AND ALLELIC FREQUENCIES.
Gene/Polymorphisms Genotypes POAG (n=75) Control (n=119) p value
APOE epsilon genotypes ε 4/4 1 (1.3%) 2 (1.7%) p=0.38       
                                                                                        ε 2/4                                    1 (1.3%)                             1 (0.8%)
                                                                                        ε 3/4                                    8 (10.7%)                          19 (16%)
                                                                                        ε 2/3                                    12 (16%)                            9 (7.6%)
                                                                                        ε 3/3                                   53 (70.7%)                        88 (73.9%)
P53 codon 72 Arg/Arg 19 (25.53%) 41 (34.5%) p=0.12
                                                                                     Arg/Pro                                44 (58.7%)                          69 (58%)
                                                                                     Pro/Pro                                  12 (16%)                             9 (7.6%)
P21 codon 31 Ser/Ser 56 (76.7%) 100 (84%) p=0.25
                                                                                      Ser/Arg                                17 (23.3%)                          19 (16%)
                                                                                     Arg/Arg                                  1 (1.4%)                                  0
Gene/Polymorphisms Alleles POAG (n=75) Control (n=119) p value
APOE epsilon alleles ε2 13 (8.7%) 10 (4.2%) p=0.14
                                                                                          ε3                                   126 (84.0%)                       204 (85.7%)
                                                                                          ε4                                     11 (7.3%)                           24 (10.1%)
The observed genotypes did not show deviation from the Hardy-Weinberg equilibrium in either the cases or the controls (p>0.05).
There were no significant differences in the distribution of APOE, p53, and p21 genotypes between the healthy subjects and
POAG patients.
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1272ε3ε3 genotypes had worse visual field results compared to
subjects with the ε3ε4 genotype. Ressiniotis et al. [22], Lake
et al. [23], and Zetterberg et al. [24] have shown that the APOE
genotype or alleles do not constitute a risk factor for POAG
and  NTG,  comparable  with  our  results.  In  the  study  of
Ressiniotis et al. [22] in English population, the frequency of
the ε3 allele was 72.6% in POAG group and 76% in control
group and the frequency of the APOE ε4 allele in their control
population  was  13.3%,  which  was  not  different  than  the
glaucoma group (14.6%). In their study, Lake et al. [23] found
no significant difference in frequency of APOE ε3 and ε4
alleles between the normal tension glaucoma group (73.9%
and 17.1%, respectively) and the control population (76.5%
and  15.5%,  respectively).  In  addition,  comparing  those
patients with progressive NTG disease to the controls revealed
no  association  between  APOE  genotype  and  the  disease
progression.  In  the  study  of  Jia  et  al.  [25],  ε2,ε3,  and  ε4
frequencies  were  found  to  be  8.75%,  82.25%  and  9%,
respectively, in Northern Chinese, which were not statistically
different  between  POAG  patients  and  control  group.  In
contrast to these studies, Junemann et al. [17] have shown a
significant association between the level of IOP and the APOE
ε2 allele in German patients, and Vickers et al. [14] showed
that the APOE ε4 allele was associated with elevated risk for
NTG in the Tasmanian population. In a recent study [18], the
frequency  of  the  APOE  ε4  allele  in  POAG  group  was
significantly higher, whereas the frequency of the APOE ε2
allele was found to be significantly lower than those in control
group in Chinese population. In contrary, Mabuchi et al. [19]
found a significantly lower frequency of the APOE ε2 and ε4
alleles in Japanese patients with OAG, and Lam et al. [20]
found lower frequency of the ε4 allele in patients with NTG,
but not with high tension glaucoma in Chinese, indicating a
protective effect of the ε4 allele against glaucoma. In a study
by Fan et al. [21], APOE ε4 carriers were found to have a
decreased NTG risk (p=0.007).
TABLE 2. MAXIMUM IOP, CUP-DISC RATIO, MD, AND PSD VALUES AMONG DIFFERENT GROUPS OF APOE, P53, AND P21
GENOTYPES.
Gene Genotype MD PSD Cup-disc ratio Maximum IOP
(mmHg)   
                                                            mean±SD
(median)
mean±SD
(median)
mean±SD
(median)
mean±SD
(median)
APOE ε2/3 -9.00±8.00
(-4.72)
5.47±4.51 (2.21) 0.58±0.22
(0.6)
27.36±4.38
(28.00)               
                                 ε2/4                 -18.62 (-18.62)        9.29
(9.29)
0.8
(0.8)
28.00 (28.00)  
                                 ε3/3                  -10.41±7.85
(-7.41)
5.40±4.06 (3.4) 0.596±0.214
(0.5)
27.01±3.49
(26.00)
                                 ε3/4                   -4.65±3.01
(-4.09)
2.23±1.41 (1.77) 0.51±0.18 (0.5) 24.62±1.99
(24.00)
                                 ε4/4                  -4.29 (-4.29)             2.62 (2.62)                0.3 (0.3)               24.00 (24.00)
                              p value                        0.09                       0.06                           0.5                           0.1
P53 codon72 Arg/Arg -10.13±7.4         
(-8.45)                      (2.45)                       (0.5)                       (25.5)
     5.33±4.54           0.56±0.21           26.8±3.1 
                              Arg/Pro           -9.71±8.1 (-7.01)     5.34±4.09 (3.4)       0.60±0.22 (0.65)        26.2±3.2 (25)
                               Pro/Pro            -8.9±7.0 (-5.63)     4.11±2.85 (2.12)      0.56±0.21 (0.55)        29±4.5 (28.5)
                               p value                        0.7                         0.9                            0.7                            0.1
P21 codon31 Ser/Ser -9.69±7.17
(-7.28)
5.25±4.16 (2.74) 0.58±0.21 (0.6) 26.91±3.53
(26.00)
                             Ser/Arg                  -9.13±9.21
(-4.97)                      (2.31)                       (0.5)
     4.58±3.61          0.57±0.20                26.56±3.59
(25.00)
                             Arg/Arg                         -                               -                     0.3 (0.3)               22.00 (22.00)
                              p value                        0.4                           0.8                          0.9                            0.7
Details of clinical features of 75 POAG patients and 119 unaffected controls for each genotype are shown in the table. IOP
indicates maximum intraocular pressure; C/D indicates cup-disc ratio of optic nerve; MD and PSD indicate visual field indices
and mean±SD (median) indicates standard deviation from the mean. There were no significant differences in maximum IOP,
MD and PSD values among different groups of p53 and p21 genotypes. POAG subjects with ε2ε3 genotype had worse visual
field defects and POAG subjects with ε3ε3 genotypes had worse MD and PSD values.
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1273As shown above, there is no consensus whether APOE
alleles  constitute  a  risk  factor  or  are  protective  against
glaucoma. There are several possible explanations for these
discrepancies [19]. APOE might have a more obvious effect
in populations exposed to different environmental factors or
with a different genetic background. The prevalence of NTG,
which has a different pathogenesis than POAG is much higher
in the Japanese population compared to others. In a previous
study, the APOE -219G and -491T have been shown to affect
optic nerve damage and visual field loss in glaucoma, which
supports the importance of APOE expression and interaction
with MYOC polymorphisms in the disease pathogenesis [38].
However, this association was not confirmed in the following
studies done in Northern China [25], Southern China [20,21],
and in England [39].
Previously, a specific functional polymorphism in exon
4 of p53 (Arg72Pro) was shown to alter its ability to induce
apoptosis in vitro, with the Arg72 variant having enhanced
apoptotic potential [40]. As the death of RGC in glaucoma has
been  proved  to  be  way  of  apoptosis,  many  investigators
examined whether common sequence variations in p53 are
associated  with  POAG  [26,27,41].  In  two  separate
populations, different polymorphic variants in p53, codon 72,
were shown to be associated with POAG, the arginine form
being a risk factor in the British population [32], and the
proline form in Chinese population with an odds ratio of 2.4
[31].  In  this  study,  we  did  not  observe  any  significant
difference in the distribution of p53 codon 72 polymorphism
between  the  control  group  and  POAG  patients,  which  is
consistent with the results of Acharya et al. [42] and Dimasi
et al. [43]. In the Indian population, the genotype distribution
was 26.8%, 50.9%, and 22.3% for Arg homozygote, Pro/Arg
heterozygote  and  Pro  homozygote,  respectively,  whereas
34.3%, 44.8% and 20.9% in the glaucoma group [42]. In the
white Australian cohort, Dimasi et al. [43] found that the p53
codon 72 Arg/Pro polymorphism was associated neither with
the development of glaucoma (high or normal tension) nor
with phenotype characteristics like age of onset or severity of
glaucoma.
DNA insult can cause activation of p21, either directly or
through transactivation by wild type p53. Cancer research has
revealed that mutations of p21 are very rare and that SNPs are
more likely to have a functional effect. The distribution of the
p21 codon 31 polymorphism differs among different ethnic
groups with a frequency of the Arg allele ranging from 4% in
the white population [35] to 50% in Chinese people [44]. Tsai
et al. [36] demonstrated that the Arg allele of the p21 codon
31 polymorphism was more frequent in POAG patients (56%)
compared  to  healthy  individuals  (36%)  in  the  Chinese
population. In our study, we could not find any association
between p21 codon 31 polymorphism and POAG, consistent
with the study of Ressiniotis et al [37]. Arg allele was found
in 8% of our control group and 13% in the POAG group. In
the  study  of  Ressiniotis  et  al  [37]  the  distribution  of  the
genotypes  in  the  control  subjects  was  61  (83.6%)  Ser
homozygotes and 12 (16.4%) Ser/Arg heterozygotes, which
was exactly the same with our control group.
The pathogenesis and genetic risk factors for glaucoma
are  not  fully  understood  yet.  Genetic  polymorphisms  in
APOE, p53, and p21 have been investigated in several studies
in  different  populations.  Polymorphisms  have  important
implications in human genetic studies and screening for such
alleles helps in the detection of a genetic predisposition to
disease.  However,  there  are  conflicting  results  about  the
association  of  these  polymorphisms  with  glaucoma
development and phenotype. The main problem in identifying
the gene variants associated with susceptibility to common
diseases  is  that  the  observed  results  are  not  replicated  in
subsequent  studies  that  used  different  populations  and/or
larger numbers of cases versus controls. This discrepancy in
the literature may reflect sampling bias, as some of the studies
have small number of subjects or it could be attributed to
ethnic disparity. Also in glaucoma studies, the inclusion of a
normotensive glaucoma group, which has risk factors other
than  elevated  IOP  and  therefore  has  a  different
etiopathogenesis,  may  make  a  study  more  sensitive  to
underlying neurodegenerative risk factors.
This  is  the  first  population  study  in  Turkish  POAG
patients for multiple polymorphisms that might be associated
with POAG. Our study found no link between polymorphisms
in  APOE,  p53,  and  p21  and  POAG  in  Turkish  subjects,
although a larger sample is required to clarify the role of these
polymorphisms in the pathogenesis and course of glaucoma
if their effects are mild.
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